⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNY News
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Chemotherapy Induced Peripheral Neuropathy (CIPN) Treatment Market Report 2026-2032: Revenues to Grow by $750M at 8.64% CAGR
globenewswire.com
ABBV
AMGN
PFE
BMY
MRK
REGN
SNY
TAK
NVS
GSK
HRTX
Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases
prnewswire.com
SNY
Cedar Health Research and Texas Native Health Expand Partnership with Embedded Clinical Research Site to Increase Patient Access to Trials
prnewswire.com
LLY
AMGN
SNY
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
globenewswire.com
SNY
U.S. Orphan Drug Market Report 2026: A $200 Billion Opportunity by 2031 - Indication, Company, Trial Phase, Marketed Status of 1400 Drugs, Drug Sales of 150 Drugs, Pricing and Dosage of 400 Drugs
globenewswire.com
BMY
GILD
JNJ
SNY
TAK
AMGN
AZN
LLY
MRK
PFE
REGN
VRTX
ABBV
ALNY
AMTX
BIIB
BMRN
CRSP
EXAS
INCY
IONS
JAZZ
NTLA
PTC
RGEN
XOM
A Decade of 18.65% CAGR Growth Ahead for AI in Regulatory Affairs Ecosystems
globenewswire.com
PFE
SNY
NVS
Sanofi announces leadership evolution in Specialty Care Business Unit
prnewswire.com
SNY
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
globenewswire.com
TEVA
SNY
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
globenewswire.com
SNY
TEVA
Sensorion Announces Leadership Changes
businesswire.com
SENS
SNY